Reactive Astrogliosis in Neonatal Rat Spinal Cord after Exposure to Cerebrospinal Fluid from Patients with Amyotrophic Lateral Sclerosis

1998 ◽  
Vol 149 (1) ◽  
pp. 295-298 ◽  
Author(s):  
Neelam Shahani ◽  
A. Nalini ◽  
M. Gourie-Devi ◽  
Trichur R. Raju
Keyword(s):  
Spinal Cord ◽  
Amyotrophic Lateral Sclerosis ◽  
Cerebrospinal Fluid ◽  
Neonatal Rat ◽  
Rat Spinal Cord ◽  
Reactive Astrogliosis ◽  
Lateral Sclerosis

Reactive astrogliosis of the spinal cord in amyotrophic lateral sclerosis

1996 ◽  
Vol 139 ◽  
pp. 27-33 ◽  
Author(s):  
Davide Schiffer ◽  
Susanna Cordera ◽  
Paola Cavalla ◽  
Antonio Migheli
Keyword(s):  
Spinal Cord ◽  
Amyotrophic Lateral Sclerosis ◽  
Reactive Astrogliosis ◽  
Lateral Sclerosis

scholarly journals Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis

2019 ◽  
Vol 139 (1) ◽  
pp. 119-134 ◽  
Author(s):  
Patrick Oeckl ◽  
Patrick Weydt ◽  
Dietmar R. Thal ◽  
Jochen H. Weishaupt ◽  
Albert C. Ludolph ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Amyotrophic Lateral Sclerosis ◽  
Cerebrospinal Fluid ◽  
Lateral Sclerosis

Chitotriosidase (CHIT1) is increased in microglia and macrophages in spinal cord of amyotrophic lateral sclerosis and cerebrospinal fluid levels correlate with disease severity and progression

2017 ◽  
Vol 89 (3) ◽  
pp. 239-247 ◽  
Author(s):  
Petra Steinacker ◽  
Federico Verde ◽  
Lubin Fang ◽  
Emily Feneberg ◽  
Patrick Oeckl ◽  
...  
Keyword(s):  
Spinal Cord ◽  
Amyotrophic Lateral Sclerosis ◽  
Cerebrospinal Fluid ◽  
Disease Progression ◽  
Underlying Disease ◽  
Therapeutic Trials ◽  
Sporadic Als ◽  
Jakob Disease ◽  
Diagnostic Sensitivity And Specificity ◽  
Lateral Sclerosis

ObjectivesNeurochemical markers of amyotrophic lateral sclerosis (ALS) that reflect underlying disease mechanisms might help in diagnosis, staging and prediction of outcome. We aimed at determining the origin and differential diagnostic and prognostic potential of the putative marker of microglial activation chitotriosidase (CHIT1).MethodsAltogether 316 patients were included, comprising patients with sporadic ALS, ALS mimics (disease controls (DCo)), frontotemporal lobar degeneration (FTLD), Creutzfeldt-Jakob disease (CJD), Alzheimer’s disease (AD), Parkinson’s disease (PD) and healthy controls (Con). CHIT1 and neurofilament levels were determined in cerebrospinal fluid (CSF) and blood and analysed with regard to diagnostic sensitivity and specificity and prognostic performance. Additionally, postmortem tissue was analysed for CHIT1 expression.ResultsIn ALS, CHIT1 CSF levels were higher compared with Con (p<0.0001), DCo (p<0.05) and neurodegenerative diseases (AD p<0.05, PD p<0.01, FTLD p<0.0001) except CJD. CHIT1 concentrations were correlated with ALS disease progression and severity but not with the survival time, as did neurofilaments. Serum CHIT1 levels were not different in ALS compared with any other study group. In the spinal cord of patients with ALS, but not Con, AD or CJD cases, CHIT1 was expressed in the corticospinal tract and CHIT1 staining colocalised with markers of microglia (IBA1) and macrophages (CD68).ConclusionsCHIT1 concentrations in the CSF of patients with ALS may reflect the extent of microglia/macrophage activation in the white matter of the spinal cord. CHIT1 could be a potentially useful marker for differential diagnosis and prediction of disease progression in ALS and, therefore, seems suitable as a supplemental marker for patient stratification in therapeutic trials.

Sign in / Sign up

Export Citation Format

Share Document